Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab Plus Utomilumab-Based Combination Therapy for Relapsed/Refractory DLBCL and MCL
NCT03440567Phase 1Completed
- Sponsor
- City of Hope
- Start
- Jun 2018
- Primary completion
- Jun 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of avelumab and utomilumab in diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) (2 cohorts), sponsored by City of Hope. Primary endpoints: Maximum Tolerated Dose at 28 days and Incidence of Adverse Events at 2 years. Started Jun 2018; status: completed.
02
Drugs
avelumabutomilumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT03440567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03440567.